Who are Vi-DT (Multi-dose formulation)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, Pandemic influenza A/H1N1 vaccine, Live Attenuated H1N1 Influenza Vaccine, Meningococcal B (Bexsero), Moderna mRNA-1273 COVID-19 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vi-dt-multi-dose-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vi-DT (Multi-dose formulation) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vi-DT (Multi-dose formulation) (Vi-DT (Multi-dose formulation)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Diseases.

phase 3 vaccine Salmonella Typhi O:1a Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

Vi-DT (Multi-dose formulation) (Vi-DT (Multi-dose formulation)) — International Vaccine Institute. Vi-DT is a vaccine that stimulates the immune system to produce antibodies against a specific target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vi-DT (Multi-dose formulation) TARGET	Vi-DT (Multi-dose formulation)	International Vaccine Institute	phase 3	vaccine	Salmonella Typhi O:1a
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Live Attenuated H1N1 Influenza Vaccine	Live Attenuated H1N1 Influenza Vaccine	University of Rochester	marketed	Live attenuated vaccine
Meningococcal B (Bexsero)	Meningococcal B (Bexsero)	University of Sao Paulo General Hospital	marketed	Recombinant protein vaccine	Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Moderna mRNA-1273 COVID-19 vaccine	Moderna mRNA-1273 COVID-19 vaccine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vi-DT (Multi-dose formulation) — Competitive Intelligence Brief. https://druglandscape.com/ci/vi-dt-multi-dose-formulation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing